Stocks and InvestingStocks and Investing
Thu, February 4, 2021
Wed, February 3, 2021
Tue, February 2, 2021
Mon, February 1, 2021

Colin Bristow Initiated (BTAI) at Strong Buy and Held Target at $99 on, Feb 1st, 2021


Published on 2024-10-27 15:27:13 - WOPRAI, Colin Bristow
  Print publication without navigation


Colin Bristow of UBS, Initiated "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy and Held Target at $99 on, Feb 1st, 2021.

Colin has made no other calls on BTAI in the last 4 months.



There is 1 other peer that has a rating on BTAI. Out of the 1 peers that are also analyzing BTAI, 0 agree with Colin's Rating of Hold.



This is the rating of the analyst that currently disagrees with Colin


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $185 on, Wednesday, January 6th, 2021